Octaplex (Human Coagulation Factor Ix, Protein C, Human Coagulation Factor Vii, Protein S, Human Coagulation F)

The product supplies human coagulation factors II, VII, IX, X together with regulatory proteins Protein C and Protein S. After intravenous infusion, these proteins re‑establish the normal cascade that converts prothrombin to thrombin, leading to fibrin formation and stable clot development.

Dosing is individualized. The prescribing clinician determines the amount and frequency based on the patient’s specific factor deficiencies, weight, severity of bleeding and laboratory coagulation results. No fixed regimen is provided in public literature.

Human coagulation factor concentrates are generally considered low risk because they are purified proteins, but safety data in pregnancy and lactation are limited. Use should be limited to situations where the benefit outweighs potential risk, and decisions are made by the treating obstetric and hematology specialists.

To request Octaplex, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Octaplex provides a combination of several clotting factors in one vial, which can be advantageous over single‑factor concentrates when multiple deficiencies exist. Compared with plasma‑derived products, it offers a more concentrated, virus‑inactivated preparation, reducing volume load and infection risk, though cost and availability may differ.

Octaplex must be stored refrigerated at 2 °C to 8 °C, protected from light, and should never be frozen or shaken. Prior to use, allow the vial to reach room temperature if required, and inspect for particulate matter or discoloration before administration.

Octaplex is supplied as a sterile liquid for intravenous infusion. It is administered by a qualified healthcare professional, typically through a controlled infusion set, with infusion rates adjusted according to patient tolerance and clinical response.

Serious adverse events include anaphylaxis, severe thromboembolic complications, disseminated intravascular coagulation, acute hemolysis and renal impairment. Immediate medical attention is required if any signs of severe hypersensitivity or unexpected clotting occur.

Octaplex is contraindicated in patients with known hypersensitivity to any of its protein components or to the stabilising excipients, and in individuals with a history of severe thrombotic events unless the benefit clearly outweighs the risk. Clinical judgement is essential for each case.